Three mainboard IPOs—Hy-Tech Engineers, Symbiotec Pharmalab and Skyways Air Services—closed Day 3 of their four-day subscription period today, with bidding set to close on August 27. Spanning the industrial engineering, pharmaceutical, and air logistics sectors respectively, these public issues offer investors exposure to three distinct and growing business segments.
Why four days? The IPOs are open from August 24 to August 27, with the additional day coming as August 26 is a settlement holiday. The holiday has shifted the usual IPO timeline, making these four-day issues
As per the latest grey market trends, Hy-Tech Engineers is signalling the highest potential listing gain at 75.47%. Symbiotec Pharmalab follows with 34.41%, while Skyways Air trails at 21.1%.
Hy-Tech Engineers is also dominating in terms of investor interest, with its issue subscribed over 50 times by the end of Day 3.
Here is a detailed breakdown of the current GMP, subscription status, and key details for each of the three IPOs.
Skyways Air vs Symbiotec Pharmalab vs Hy-Tech Engineers IPO GMP Compared
| IPO | GMP | Upper Price Band | Estimated Listing Price | Implied Listing Gain |
| Hy-Tech Engineers | Rs 40 | Rs 53 | Rs 93 | 75.47% |
| Symbiotec Pharmalab | Rs 340 | Rs 988 | Rs 1,328 | 34.41% |
| Skyways Air | Rs 29 | Rs 138 | Rs 167 | 21.1% |
Note: GMP figures are unofficial, speculative and may change before listing. They do not represent official exchange data.
Market participants are keeping a keen eye on demand metrics, overall market sentiment, and GMP movements to gauge potential debut performance.
ALSO READ: Augmont Enterprises IPO Allotment: Date And How To Check On BSE, NSE And MUFG Intime India
Hy-Tech Engineers IPO GMP, Subscription Status And Key Details
Hy-Tech Engineers, a manufacturer of industrial components and hydraulic fittings, is currently commanding a GMP of Rs 40 as of 4:30 p.m. today. When added to the upper price band of Rs 53, this projects a listing price of Rs 93—a strong 75.47% premium.
- Subscription Status: The issue has seen massive demand, subscribed 50.86 times on Wednesday.
- Issue Size: Rs 135.73 crore (Rs 60 crore fresh issue + Rs 75.73 crore OFS).
- Lot Size & Investment: Minimum 283 shares (Rs 14,999).
- Key Dates: Allotment expected on August 28; listing on BSE and NSE on September 1.
Symbiotec Pharmalab IPO GMP, Subscription Status And Key Details
Symbiotec Pharmalab, which operates in the active pharmaceutical ingredient (API) segment, is commanding a GMP of Rs 340. Paired with its upper price cap of Rs 988, shares could debut at Rs 1,328, suggesting a solid 34.41% listing gain.
- Subscription Status: The public issue has been subscribed 5.31 times at thhe end of bidding on Wednesday, showing steady initial interest.
- Issue Size: Rs 1,757 crore (Rs 150 crore fresh issue + Rs 1,607 crore OFS).
- Lot Size & Investment: Minimum 15 shares (Rs 14,820).
- Key Dates: Allotment expected on August 28; listing on BSE and NSE on September 1.
Skyways Air Services IPO GMP, Subscription Status And Key Details
Specialising in global freight forwarding and supply chain logistics, Skyways Air Services is commanding a GMP of Rs 29 in the unofficial market. Factoring in the upper price band of Rs 138, the estimated listing price is Rs 167, indicating a potential 21.1% gain.
- Lot Size & Investment: Minimum 100 shares (Rs 13,800).
- Key Dates: Allotment expected on August 28; listing on BSE and NSE on September 1.
Symbiotec Pharmalab vs Hy-Tech Engineers vs Skyways Air: Which IPO Signals The Highest Listing Gain?
Based on current grey market trends, Hy-Tech Engineers leads both in percentage gain and estimated absolute profit per retail lot.
With a Rs 40 GMP on a Rs 53 issue price, it implies a 75.47% gain. Given the 283-share lot size, a retail investor could see an estimated profit of Rs 11,320 per lot (Rs 40 × 283). Symbiotec Pharmalab takes the second spot, offering an estimated gain of Rs 5,100 per 15-share lot. Skyways Air rounds out the trio with a projected profit of Rs 2,900 per 100-share retail lot.
Disclaimer: Investing in IPOs carries market risks. Ensure you consult a financial advisor and review the red herring prospectus before participating.
Note: GMP figures are speculative and do not reflect official exchange data.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
